E
ExcepGen
Biotechnology company solving fundamental underlying problems in drug discovery to create a new generation of therapeutics
About ExcepGen
ExcepGen operates in the biotechnology sector, focusing on the development of advanced nucleic acid therapeutics. The company serves pharmaceutical firms and research institutions by providing a unique platform that modifies how cells respond to DNA and mRNA, aiming to create more effective drugs and vaccines. ExcepGen's business model revolves around licensing its technology and forming strategic partnerships with industry leaders. Revenue is generated through licensing fees, research collaborations, and milestone payments. The company is driven by a team of visionary scientists dedicated to improving human health by exploring foundational principles of biology. ExcepGen fosters a culture of curiosity and interdisciplinary collaboration, seeking individuals who can bridge the gaps between biochemistry, cell biology, and therapeutic design.
Source: Dealroom company dataAt a glance
- Founded
- 2017
- Headquarters
- San Francisco, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
Y Combinator
Pi Campus
RA Capital Management
Apollo projects
Gravity Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ExcepGen on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ExcepGen on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.